Dietary Intake of Salmon and Bone Health

NCT02615301 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 122

Last updated 2015-11-26

No results posted yet for this study

Summary

The aims of this study were to investigate how intake of tailor-made salmon affected bone biomarkers, nutritional status, as well as body composition and bone mineral density. The 122 healthy postmenopausal women included in this 12 weeks intervention study were randomized into four groups: three salmon groups (with three different vitamin D3/vitamin K1 combinations) and one tablet group (vitamin D and Calcium).

Conditions

Interventions

DIETARY_SUPPLEMENT

Tailor-made salmon with high levels of vitamin D3 and K1

The aims were to investigate how intake of tailor-made salmon with high levels of vitamin D3 and K1 affected bone biomarkers, nutritional status (vitamin D, omega-3), as well as body composition and bone mineral density.

DIETARY_SUPPLEMENT

Tailor-made salmon with low levels of vitamin D3 and high K1

The aims were to investigate how intake of tailor-made salmon with low levels of vitamin D3 and high K1 affected bone biomarkers, nutritional status (vitamin D, omega-3), as well as body composition and bone mineral density.

DIETARY_SUPPLEMENT

Tailor-made salmon with high levels of vitamin D3 and low K1

The aims were to investigate how intake of tailor-made salmon with high levels of vitamin D3 and low K1 affected bone biomarkers, nutritional status (vitamin D, omega-3), as well as body composition and bone mineral density.

DIETARY_SUPPLEMENT

Supplement with vitamin D and Calcium

The aims were to investigate how supplement with vitamin D and Calcium affected bone biomarkers, nutritional status (vitamin D, omega-3), as well as body composition and bone mineral density.

Sponsors & Collaborators

  • Haukeland University Hospital

    collaborator OTHER
  • National Institute of Nutrition and Seafood Research, Norway

    lead OTHER_GOV

Principal Investigators

  • Ingvild E Graff, PhD · NIFES, postboks 2029 Nordnes, 5815 Bergen, Norway

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
50 Years
Max Age
64 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-01-31
Primary Completion
2009-06-30
Completion
2009-06-30

Countries

  • Norway

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02615301 on ClinicalTrials.gov